New York State Common Retirement Fund Sells 208 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

New York State Common Retirement Fund cut its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 0.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,685 shares of the medical instruments supplier’s stock after selling 208 shares during the quarter. New York State Common Retirement Fund owned approximately 0.12% of LeMaitre Vascular worth $1,515,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Congress Asset Management Co. MA boosted its stake in LeMaitre Vascular by 36.3% in the 3rd quarter. Congress Asset Management Co. MA now owns 508,379 shares of the medical instruments supplier’s stock worth $27,696,000 after purchasing an additional 135,266 shares during the period. Ranger Investment Management L.P. lifted its holdings in shares of LeMaitre Vascular by 15.8% in the third quarter. Ranger Investment Management L.P. now owns 898,822 shares of the medical instruments supplier’s stock worth $48,968,000 after buying an additional 122,601 shares in the last quarter. Conestoga Capital Advisors LLC boosted its position in shares of LeMaitre Vascular by 3.0% during the third quarter. Conestoga Capital Advisors LLC now owns 1,917,581 shares of the medical instruments supplier’s stock worth $104,470,000 after acquiring an additional 55,895 shares during the last quarter. Algert Global LLC grew its stake in LeMaitre Vascular by 818.0% during the third quarter. Algert Global LLC now owns 50,950 shares of the medical instruments supplier’s stock valued at $2,776,000 after acquiring an additional 45,400 shares in the last quarter. Finally, Envestnet Asset Management Inc. increased its holdings in LeMaitre Vascular by 24.8% in the 3rd quarter. Envestnet Asset Management Inc. now owns 195,983 shares of the medical instruments supplier’s stock valued at $10,677,000 after acquiring an additional 38,958 shares during the last quarter. 84.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at LeMaitre Vascular

In other news, Director David B. Roberts sold 5,025 shares of the firm’s stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $75.62, for a total value of $379,990.50. Following the sale, the director now directly owns 14,114 shares in the company, valued at approximately $1,067,300.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other LeMaitre Vascular news, Director David B. Roberts sold 5,025 shares of LeMaitre Vascular stock in a transaction on Monday, May 6th. The shares were sold at an average price of $75.62, for a total value of $379,990.50. Following the transaction, the director now directly owns 14,114 shares of the company’s stock, valued at $1,067,300.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director John A. Roush sold 7,500 shares of the stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $69.00, for a total value of $517,500.00. Following the sale, the director now owns 2,278 shares of the company’s stock, valued at approximately $157,182. The disclosure for this sale can be found here. Insiders have sold a total of 195,967 shares of company stock valued at $14,072,324 over the last quarter. 10.79% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research analysts have commented on LMAT shares. StockNews.com raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. KeyCorp started coverage on LeMaitre Vascular in a report on Tuesday, February 6th. They set a “sector weight” rating for the company. JMP Securities upped their price objective on LeMaitre Vascular from $72.00 to $77.00 and gave the stock a “market outperform” rating in a report on Friday, May 3rd. Barrington Research raised their target price on shares of LeMaitre Vascular from $69.00 to $79.00 and gave the company an “outperform” rating in a report on Friday, May 3rd. Finally, Stifel Nicolaus upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and increased their price objective for the company from $59.00 to $75.00 in a research report on Friday, April 26th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, LeMaitre Vascular presently has an average rating of “Moderate Buy” and a consensus target price of $73.83.

LeMaitre Vascular Trading Up 1.3 %

Shares of NASDAQ:LMAT opened at $76.00 on Friday. The company has a market capitalization of $1.71 billion, a price-to-earnings ratio of 50.33, a PEG ratio of 2.99 and a beta of 0.88. LeMaitre Vascular, Inc. has a 12 month low of $44.27 and a 12 month high of $76.24. The firm’s 50-day moving average is $66.67 and its 200 day moving average is $59.46.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.05. The firm had revenue of $53.48 million for the quarter, compared to the consensus estimate of $51.50 million. LeMaitre Vascular had a return on equity of 11.57% and a net margin of 16.99%. The company’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same period in the prior year, the business posted $0.27 earnings per share. As a group, equities analysts forecast that LeMaitre Vascular, Inc. will post 1.77 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 30th. Shareholders of record on Thursday, May 16th will be given a dividend of $0.16 per share. The ex-dividend date of this dividend is Wednesday, May 15th. This represents a $0.64 annualized dividend and a yield of 0.84%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 42.38%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.